EPICS Therapeutics Chief Executive Officer and Chief Scientific Officer Graeme Fraser, PhD, and Director of Business Development Brett Whitecross, will attend BIO-Europe 2025 in Vienna from November 3–5, 2025. They will meet with collaborators and investors to discuss EPICS’s METTL3 inhibitor program and ongoing advances in RNA epigenetic therapy.
NEWS & EVENTS